NanoMn®_COVID-19 A Prospective, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blind Trial to Evaluate the Clinical Efficacy of NanoManganese® on Top of Standard of Care, in Adult Patients With Moderate to Severe Coronavirus Disease 2019 (COVID-19)

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 4, 2022

Primary Completion Date

October 4, 2022

Study Completion Date

December 1, 2022

Conditions

COVID-19 Pandemic

Interventions

DRUG

Placebo

The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette

DRUG

Experimental drug

The administration of the treatment consists in a deposit in the gingivo-jugal groove of each cheek with a graduated pipette

Trial Locations (1)

Santa Casa BH, Belo Horizonte